|Bid||0.1750 x 0|
|Ask||0.1850 x 0|
|Day's range||0.1750 - 0.1850|
|52-week range||0.1300 - 0.4500|
|Beta (5Y monthly)||0.45|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon-targeted formulation (3FDC).
The last twelve months have seen exciting developments as Anatara Lifesciences Ltd (ASX:ANR) advances our lead human health product, our Gastrointestinal ReProgramming (GaRP) complementary medicine.
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on challenge trials of select Anatara animal health assets.